Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003584 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy With or Without Prednisone in Treating Patients With Recurrent and/or Metastatic Kidney Cancer
A Phase 2 study, sponsored by University of New Mexico.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT00003584 is a Phase 2 study that has completed, run by University of New Mexico. The registered enrollment target is 35 participants.
The verdict
NCT00003584, a Phase 2 study, has completed, sponsored by University of New Mexico.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Prednisone may help to relieve symptoms in patients with recurrent and/or metastatic kidney cancer. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy consisting of vinorelbine and estramustine with or without prednisone in treating patients who have recurrent and/or metastatic kidney cancer.
Interventions
- DRUG prednisone
- DRUG vinorelbine tartrate
- DRUG estramustine phosphate sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 1998-07 |
| Est. Completion | 2000-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003584
The ClinicalTrials.gov registry entry for NCT00003584 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of New Mexico, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which prednisone is the first listed.
NCT00003584 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003584 about?
NCT00003584 is a clinical study titled "Combination Chemotherapy With or Without Prednisone in Treating Patients With Recurrent and/or Metastatic Kidney Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Prednisone may help to relieve symptoms in patients with recurrent and/or metastatic kidney cancer. PURPOSE: Phase II trial...
What is the current status of trial NCT00003584?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 1998-07. Estimated completion is 2000-12.
What interventions are being tested in trial NCT00003584?
The interventions under investigation include: prednisone (DRUG), vinorelbine tartrate (DRUG), estramustine phosphate sodium (DRUG).
Who is sponsoring clinical trial NCT00003584?
This trial is sponsored by University of New Mexico, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.